| Display title | Chemistry:Setanaxib |
| Default sort key | Setanaxib |
| Page length (in bytes) | 16,204 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 286032 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | Jworkorg (talk | contribs) |
| Date of page creation | 21:29, 5 February 2024 |
| Latest editor | Jworkorg (talk | contribs) |
| Date of latest edit | 21:29, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Setanaxib (development code GKT-831) is an experimental orally bioavailable dual inhibitor of NADPH oxidase isoforms NOX4 and NOX1. Setanaxib is a member of the pyrazolopyridine dione chemical series. The compound is the only specific NOX inhibitor that has entered into clinical trials.
Setanaxib has... |
